Learn more

ESTEVE PHARMACEUTICALS SA

Overview
  • Total Patents
    225
  • GoodIP Patent Rank
    6,867
  • Filing trend
    ⇧ 31.0%
About

ESTEVE PHARMACEUTICALS SA has a total of 225 patent applications. It increased the IP activity by 31.0%. Its first patent ever was published in 2010. It filed its patents most often in EPO (European Patent Office), United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are LANDOS BIOPHARMA INC, AMITECH THERAPEUTIC SOLUTIONS INC and FAKO ILACLARI A S.

Patent filings per year

Chart showing ESTEVE PHARMACEUTICALS SAs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Almansa-Rosales Carmen 140
#2 Virgili-Bernado Marina 33
#3 Alonso-Xalma Monica 24
#4 Cuevas-Cordobés Félix 23
#5 Garcia-Lopez Monica 22
#6 Alegret-Molina Carlos 20
#7 Christmann Ute 13
#8 Tesson Nicolas 13
#9 Ribera Sanchez Albert 12
#10 Garcia Lopez Monica 12

Latest patents

Publication Filing date Title
WO2021069339A1 Homopiperazinyl and homopiperidinyl quinazolin-4(3h)-one derivatives having multimodal activity against pain
WO2021018824A1 Use of (r)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one for the treatment of nociceptive pain, neuropathic pain, osteoarthritis pain and cancer pain, while having reduced side effects compared to opioids
WO2020229502A1 Use of co-crystals of tramadol and celecoxib for treating pain while reducing the abuse liability of tramadol
TW202039856A Methods for the manufacture of recombinant viral vectors
WO2020157026A1 Hydroxylated derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
WO2020127678A1 Recombinant vectors for the long term treatment of mucchopolysacharidosis
WO2020120606A1 New pyrrolidine-2-carboxylic acid derivatives for treating pain and pain related conditions
TW202026281A New pyrrolidine-2-carboxylic acid derivatives for treating pain and pain related conditions
WO2020115045A1 Substituted 1h-benzo[d]imidazole derivatives having multimodal activity against pain and pain related conditions
WO2020099548A1 Animal model of mucopolysaccharidoses type iva
WO2020089478A1 New tetrahydropyrimidodiazepin and tetrahydropyridodiazepin compounds for treating pain and pain related conditions
TW202031264A New alcoxyaminopyridine derivatives for treating pain and pain related conditions
WO2020089397A1 Substituted quinazolin-4(3h)-one derivatives having multimodal activity against pain
TW202035391A Compound, process for preparation of compounds, use of the compounds, pharmaceuticalcomposition, compound for use as a medicament, and compound for use as a medicament for the treatment of pain
WO2020089263A1 Optionally nitrogenated isoquinolin-1(2h)-ones and 1h-isochromen- 1-ones for treating pain and pain related conditions
WO2020021015A1 New imidazopyridine derivatives for treating pain and pain related conditions
WO2020021021A1 Ortho substituted phenoxypropylamino and benzyloxypropylamino derivatives having multimodal activity against pain
WO2020016315A1 Fused dihydroindazole derivatives having multimodal activity against pain
EP3753932A1 Substituted bicyclic derivatives having multimodal activity against pain
KR20210027266A Adeno-associated virus vector for the treatment of mucopolysaccharide accumulation syndrome IV type A